Table 2.
Incidence of adverse events
| Events | Cell treatment group (n = 17) | Control group (n = 18) | Total (n = 35) | p value |
|---|---|---|---|---|
| Any adverse eventa | 14 (82.4%) | 15 (83.3%) | 29 (82.9%) | >0.999 |
| Fevera | 8 (47.1%) | 5 (27.8%) | 13 (37.1%) | 0.305 |
| Hemoptysisa,b | 3 (17.6%) | 6 (33.3%) | 9 (25.7%) | 0.443 |
| Sputum increaseda | 4 (23.5%) | 3 (16.7%) | 7 (20.0%) | 0.691 |
| Cough increaseda | 3 (17.6%) | 3 (16.7%) | 6 (17.1%) | >0.999 |
| Fatiguea | 3 (17.6%) | 3 (16.7%) | 6 (17.1%) | >0.999 |
| COVID-19a | 2 (11.8%) | 4 (22.2%) | 6 (17.1%) | 0.658 |
| Bronchiectasis exacerbationa | 2 (11.8%) | 2 (11.1%) | 4 (11.4%) | >0.999 |
| Pharyngeal discomforta | 1 (5.9%) | 3 (16.7%) | 4 (11.4%) | 0.603 |
| Othera,c | 4 (23.5%) | 5 (27.8%) | 9 (25.7%) | >0.999 |
| Serious adverse eventsa,d | 2 (11.8%) | 0 (0) | 2 (5.7%) | 0.229 |
a
Data were presented as patient number (percentage of patients).
b
The term “hemoptysis” included bloody sputum in this study.
c
Other adverse events included chest discomfort, dizziness, dyspnea, nausea, influenza, and anxiety.
d
Serious adverse events occurred in 2 patients, one for pneumothorax and another for acute exacerbation of COPD.